Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS32015 Combination Therapy in Multiple Myeloma
NCT07018050Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QLS32015 in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Started Sep 2025; status: recruiting.
02
Drugs
QLS32015
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07018050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018050.